Pharmafile Logo
Pharmafocus logo
Advanced Search

2009 financials

Showing 14 posts of 14 posts found.

UCB

Generic Keppra hits UCB sales

March 3, 2010
Sales and Marketing 2009 financials, Keppra, UCB

UCB’s sales fell 13% in 2009 as the pharma company faced the first full year of generic competition in the …

News

Zeltia continue strong growth

February 26, 2010
Sales and Marketing 2009 financials, PharmaMar, Yondelis, Zeltia

Consolidated revenues at Spanish biopharmaceutical company Zeltia increased by 17% to 123.4 million euros enabling it to halve operating losses. …

News

Bayer pharma sales overcome European decline

February 26, 2010
Sales and Marketing 2009 financials, Bayer, Xarelto

Bayer’s group sales dropped 5% to 31 billion euros in a “difficult year” for the company that saw a drop …

News

Merck KGaA posts modest revenue increase

February 24, 2010
2009 financials, Erbitux, Merck KGaA, Merck Serono, Rebif

German pharma company Merck has posted a modest rise in revenue amidst strong pharma growth.  Revenues increased 2.1% to 7.7 …

News
Shire's Adderall

Low Adderall sales hit Shire

February 22, 2010
Sales and Marketing 2009 financials, Adderall, Shire

Shire has posted negative growth due to generic competition for its flagship ADHD drug Adderall XR. Product sales were down …

News
Sleep disorder treatment Provigil

Cephalon posts strong figures

February 12, 2010
Sales and Marketing 2009 financials, Cephalon

US–based specialty pharma company Cephalon, best known for its sleep disorder treatment Provigil, has posted an 11% increase in sales …

News

Strong showing for Sanofi-Aventis in 2009

February 11, 2010
2009 financials, Sanofi-Aventis

Sanofi-Aventis made large gains in emerging markets, vaccines and consumer healthcare last year, helping produce 8.5 billion euros in net …

News
Andrew Witty

GSK confirms job cuts but avoids specifics

February 5, 2010
Research and Development, Sales and Marketing 2009 financials, GlaxoSmithKline

GlaxoSmithKline has sidestepped questions about the internal fall-out from its new plan to slash R&D infrastructure costs. Presenting the company’s …

News

Zeftera problems weigh down Basilea

February 5, 2010
Sales and Marketing 2009 financials, Basilea, Zeftera

Specialist Swiss pharma company Basilea has announced a doubling of its revenues in 2009, thanks to the launch of its …

News
Pfizer World

Wyeth acquisition yet to shake Pfizer’s Lipitor dependence

February 4, 2010
Sales and Marketing 2009 financials, Lipitor, Pfizer

Pfizer’s profits rose by 7% last year on the back of a 4% increase in revenue driven by cholesterol treatment …

News
Roche building

Genentech integration hits Roche profits

February 3, 2010
Sales and Marketing 2009 financials, Genentech, Roche

Roche achieved healthy sales growth in 2009 but saw a 22% drop in net income due to the cost gaining …

News

Novo buoyed by insulin portfolio

February 2, 2010
Sales and Marketing 2009 financials, Novo Nordisk, Victoza

Danish pharma company Novo Nordisk managed a double-digit rise in sales and profits in 2009, buoyed by insulin products NovoRapid, …

News

Healthy growth for Lilly but Effient doubts raised

February 1, 2010
Sales and Marketing 2009 financials, lilly

Lilly’s revenues for the full year rose 7% in 2009, thanks to a growth in sales of Zyprexa, the flagship …

News

BMS profits buoyant after Mead Johnson jettisoned

February 1, 2010
Sales and Marketing 2009 financials, BMS, Mead Johnson

Bristol-Myers Squibb’s have revealed continued strong sales of the anti-blood clotting treatment Plavix and the antipsychotic Abilify and a huge …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024